In this study, the response of CTLA4 and PD-1 treatment in glioma was evaluated, and difference was found between high- and low-grade glioma groups, hinting that anti-CTLA4 or anti–PD-1 drugs might be a good method for high-grade glioma patients. Here, CTLA4 is linked to central nervous system cancer.